Contralateral Occluded Carotid Defines Revascularization Strategy

A significative lesion to the carotid artery in addition to contralateral carotid occlusion is an obvious factor of high risk for a revascularization procedure. However, this might be true for surgery but not for carotid artery stenting according to this recent publication in JACC.

Carótida ocluida contralateral define la estrategia de revascularización

The presence of contralateral carotid occlusion has been established as high risk for patients undergoing carotid endarterectomy, even though recent observational studies have cast a shadow on this paradigm. 

The aim of this study was to determine the clinical impact of contralateral occlusion in contemporary patients receiving endarterectomy or carotid artery stenting.  

All patients from a national registry receiving carotid revascularization presenting contralateral occlusion were included. 

Primary end point was a combination of death, stroke and MI.


Read also: Solution for Type 1A Endoleaks After Abdominal Endoprosthesis.


Of 58423 patients undergoing carotid revascularization, 7.9% (n=4624) had contralateral occlusion. Among these, 68.9% (n=3185) received surgery and 31.1% (n=1439) carotid artery stenting. Nearly half of patients (45.4%) presented with symptomatic disease because of prior stroke of transient ischemic attack. 

After multiple adjustments of different variables, researchers observed that a history of contralateral occlusion was associated with 71% increased events risk after endarterectomy (p<0.001), vs. no increased risk with carotid artery stenting (OR 0.94; CI 95%, p=0.64).

Conclusion

Contralateral carotid occlusion is an important risk factor for patients undergoing endarterectomy but no for patients receiving carotid artery stenting. This factor should be taken into account when deciding for or against a revascularization strategy. 

Original Title: Clinical Impact of Contralateral Carotid Occlusion in Patients Undergoing Carotid Artery Revascularization.

Reference: Anna K Krawisz et al. J Am Coll Cardiol. 2021 Feb 23;77(7):835-844. doi: 10.1016/j.jacc.2020.12.032.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...